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Abstract
Background: As malaria transmission intensity approaches zero, measuring it becomes progressively more difficult
and inefficient because parasite-positive individuals are hard to detect. This situation may arise shortly before
achieving local elimination, or during surveillance post-elimination to prevent reintroduction. Antibody responses
against the parasite last longer than the infections themselves. This “footprint” of infection may thus be used for
assessing transmission intensity. A statistical approach is presented for measuring the seroconversion rate (SCR), a
correlate of the force of infection, from individual-level longitudinal data on antibody titres in an area of low
Plasmodium falciparum transmission.
Methods: Blood samples were collected from 160 Indonesian schoolchildren every month for six months. Titres of
antibodies against AMA-1 and MSP-119 antigens of P. falciparum were measured using ELISA. The distribution of
antibody titres among seronegative and -positive individuals, respectively, was estimated by comparing the titres
from the study data (a mixture of both seropositive and -negative individuals) with titres from a (unexposed)
negative control group of Indonesian individuals. Two Markov-Chain models for the transition of individuals
between serological states were fitted to individual anti-PfAMA-1 or anti-PfMSP-1 titre time series using Bayesian
Markov-Chain-Monte-Carlo (MCMC). This yielded estimates of SCR as well as of the duration of seropositivity.
Results: A posterior median SCR of 0.02 (Pf AMA-1) and 0.09 (PfMSP-1) person-1 year-1 was estimated, with credible
intervals ranging from 1E-4 to 0.2 person-1 year-1. This level of transmission intensity is at the lower range of what
can reliably be measured with the present study size. A Bayesian test for seroconversion of an individual between
two observations is presented and used to identify the subjects who have most likely experienced an infection.
Furthermore, the theoretical limits of measuring transmission intensity, and how these depend on duration and size
of a study as well as on transmission intensity itself, is illustrated.
Conclusions: This analysis shows that it is possible to measure SCR's from individual-level longitudinal data on
antibody titres. In addition, individual seroconversion events can be identified, which can be useful in assessing
interruption of transmission. Analyses of further serological datasets using the present method are required to
improve and validate it. This includes measurement of the duration of antibody responses, how it depends on host
age or cumulative exposure, or on the particular antigen used.
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Background
Human malaria caused by the Plasmodium falciparum
parasite is a public health priority in many sub-tropical
and tropical areas. Intervention programs aiming at ei-
ther reduction of malaria transmission intensity to
minimize morbidity and mortality (“control”) or aiming
at local interruption of parasite transmission (“elimin-
ation”) require continuous monitoring of transmission
levels [1].
A natural measure of transmission intensity is the
force of infection parameter (FOI), which corresponds to
the number of infections acquired per person per year.
More familiar is the entomological inoculation rate (EIR,
number of infectious mosquito bites per person and
year). EIR values tend to be higher than values of FOI,
because not all mosquito bites result in an infection.
Parasite prevalence (the proportion of the population
which is parasite positive) increases monotonically with
EIR but saturates at high transmission levels. At medium
to high FOI these quantities may be directly measured
from data on presence of the parasite: the number of
sporozoite-positive mosquitoes which bite a person per
night can be used to estimate EIR, and diagnostic
methods for detection of parasites in the human popula-
tion – such as microscopy, rapid diagnostic tests (RDT)
or polymerase chain reaction (PCR) – yield estimates of
parasite prevalence. At very low transmission intensities,
however, detection of the parasite itself becomes very in-
efficient: enormous study populations would be required
in order to find enough parasite-positive individuals.
Similarly, large numbers of mosquitoes would need to
be captured in order to gain reliable EIR estimates [2].
The presence of antibodies against the parasite, in con-
trast, has classically been used to measure transmission
at low levels, and correlates well with EIR [3,4]. How
long this “footprint” of an infection persists is debated,
but even in the worst case antibodies are present in
blood longer than the parasite itself [5]. The seroconver-
sion rate (SCR, the number of individuals which become
seropositive per person and year) thus constitutes an al-
ternative measure of transmission intensity [6]. The con-
version factor between FOI and SCR is equal to the
proportion of infections which give rise to a detectable
immune response, which may differ depending on
the laboratory methods used. Serological data thus
summarizes information on past exposure and should
allow for measurement of the FOI using much smaller
study populations, without the requirement for direct
detection of parasites. Mathematically, the temporal
change in the proportion of seropositives, s, can be
described by the differential equation
ds
dt
¼ λ 1 sð Þ  ρs; ð1Þ
With λ denoting the SCR, and ρ denoting the rate of
seroreversion. The solution of the differential equation,
assuming that at t = 0 the whole population is seronega-
tive, indicates the proportion positive after time t as
s tð Þ ¼ λ
λþ ρ 1 e
 λþρð Þt
 
ð2Þ
This model, often called the “reversible catalytic
model” [7] can be used to estimate SCR from the in-
crease of seroprevalence with host age in cross-sectional
data, considering that age is simply time since birth.
Indeed, this method has been shown to yield good
estimates of transmission intensity, which correlate well
with EIR estimates from the same locations and capture
geographic and temporal changes in FOI [4,8]. However,
it is not suited to detecting single conversion events,
partly because individual-level information is lost when
converting continuous antibody titre measurements to a
prevalence for each age group.
Serological cohort studies provide an interesting alter-
native: because the serological status of individuals is
known at a minimum of two time points single infection
events may be identified, allowing the measurement of
low level transmission. Beyond measuring transmission
intensity, analyses of serological cohort-data have the
potential to improve the understanding of the dynamics
of antibody responses.
However, serological data is very noisy: measured anti-
body levels may vary due to natural causes unrelated to
malaria, such as stress or other infections, or due to
small random errors in the processes of sample collec-
tion and laboratory analysis. As a consequence of this,
using a fixed titre threshold to assign serological status
is problematic in longitudinal data: some individuals
may repeatedly pass the threshold merely due to small
fluctuations in antibody levels, creating “false” conver-
sion and reversion events. Consequently, a noise-robust
statistical approach was used for the present analysis of
a cohort of 160 Indonesian schoolchildren. A Hidden
Markov Model (HMM) was fitted to the data in a two-
step procedure: the titre distributions among negative
and positive individuals, respectively, were estimated
using a non-parametric Bayesian approach [9,10]. This
allows assigning a probability of being seropositive to
individuals, thus avoiding strict classification. Subse-
quently, the rates of transition between positive and
negative states (the conversion and reversion rates) were
estimated by Bayesian Markov Chain Monte Carlo
(MCMC).
Methods
Study site and data collection
The present study was conducted in the district of
Purworejo, Central Java Province, Indonesia, between
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December 2008 and June 2009. The area is characterized
by low and seasonal malaria transmission, with higher
intensity during the rainy season from October to
March, and very low instensity during the dry season
(April to August). A rolling cross-sectional study involv-
ing approximately 500 subjects indicated that the peak
of monthly P. falciparum prevalence occurred during
December 2008 (1.08%) while during the dry season
almost no parasites were detected by microscopy
(Supargiyono, unpublished). A total of 500 schoolchil-
dren of age 10–11 was enrolled and tested for the pres-
ence of antibodies to P. falciparum. All children
seropositive for at least one antigen at the December
collection (n = 57), children with parasites during the co-
hort observation (n = 13) and a randomly chosen add-
itional 90 seronegative individuals were selected for
serological follow up, yielding a cohort of 160 indivi-
duals. Blood smears were taken weekly for 30 weeks for
parasite microscopy. Parasitaemic individuals were al-
ways treated. Blood spots for serological analysis were
collected monthly, from December 2008 to July 2009,
on pre-labelled chromatographic filter paper (3 MM;
Whatman, Maidstone, UK), and stored at −20C until
analysis. Ethical approval was received by the local insti-
tutional review board and written consent was received
from the parents or guardians of the children.
Microscopy and ELISA
Blood thick smears were stained with 5% Giemsa and a
blood volume corresponding to at least 200 leucocytes
was examined by a trained microscopist. Parasite density
was calculated assuming 8000 leucocytes/μl. Blood spot
samples collected on filter paper were cut in circles with a
diameter of 3.5 mm (equivalent to 1.5 μl serum) and
eluted with PBS-Tween (0.05%), as described previously
[11], in preparation for analysis by enzyme-linked im-
munosorbent assay (ELISA). Antibody titres were
measured using indirect ELISA as described in [12], using
the P. falciparum merozoite surface protein 119 (MSP-
119,) and P. falciparum apical membrane antigen 1
(AMA-1) recombinant proteins. Briefly, the PfMSP-1 and
PfAMA-1 antigens were coated on plates at the concen-
tration of 0.5 μg/mL in carbonate-bicarbonate coating buf-
fer (pH 9.6) and incubated at 4C overnight. After
washing plates were blocked with 1% (w/v) skimmed milk
solution for 3 hours. Samples were added in duplicate at a
dilution of 1:1000 and a positive control pool of hyper-
immune sera were added to each plate. After incubation
overnight at 4C, the plates were washed, horseradish-
peroxydase-conjugated rabbit-anti-human IgG (DAKO,
Roskilde, Denmark) was added, and plates were incubated
for 3 hours. O-phenylenediamine was used as a substrate
and the reactions were stopped by adding 25 μl 2 M
H2SO4. Optical density was read at 450 nm.
Data preparation
The raw OD data were converted to titre values by
using a calibration curve generated by the positive
control sera run on each plate. Only data of parti-
cipants who were present at the six survey rounds
from December to May were used for statistical ana-
lysis. Antibody data from the June survey was discar-
ded due to a high proportion of missing values. This
reduced the number of individuals in the data to 137,
and the number of surveys to 6.
Finite mixture models
Individuals are typically classified as seropositive if their
antibody titre is higher than the mean of a control group
plus two or three standard deviations [8,13]. However,
this may yield biased estimates as some positive
individuals may fall below this threshold while some
negative individuals may exceed it. Subtle changes in
actual antibody levels over time, perhaps due to co-
infection with another pathogen, combined with small
variation in the laboratory assays may be the reasons for
such misclassification. The problem becomes particu-
larly acute when considering longitudinal data (cohort
studies): a single individual may - over the course of
several observations - repeatedly pass the threshold even
though the associated titre value was merely subject to
noise and the underlying serological status essentially
did not change. It is thus necessary for the analysis of
longitudinal data to use a method of classification, which
is robust against small changes in antibody titre.
“Finite Mixture Models” [14] provide a statistical
framework for the analysis of data where the distribution
of a continuous response variable, such as antibody titre,
reflects the mixture of two or more classes of
individuals, which have different but potentially overlap-
ping responses. The overall distribution of antibody
titres in the dataset (described by the probability density
function (PDF) f(x)) is seen as a mixture of the titre dis-
tribution among negative individuals (with PDF g–(x))
and the distribution among positives (with PDF g+(x)).
With the mixing parameter π – the seroprevalence – the
distribution of titres can be written as
f xð Þ ¼ 1 πð Þg xð Þ þ πgþ xð Þ: ð3Þ
In words: the PDF of the overall titre distribution is a
weighted average of the titre distributions in the positive
and negative classes.
Mixture decomposition
The method of [9] was used to estimate the mixture
parameters. It requires a statistical sample of titre values
from an unexposed control group. The titre distribution
among controls is compared to the distribution in the
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field data, which is known to comprise a mixture of
positive and negative individuals. The most likely val-
ues for the titre distribution among positives, negati-
ves, and the mixing ratio (seroprevalence) can then be
determined.
An implementation for use with WINBUGS software
[15] and documentation can be found at [16]. The ap-
proach is non-parametric, meaning that no particular
shapes of the distributions g–(x) and g+(x) have to be
assumed. Instead, the titre values are grouped into
ordered categories, and parameter estimation is subject
to the two constraints that i) the odds of being positive,
g+(x)/g-(x), are strictly increasing with titre, and ii) that
there are no positives in the category with the lowest
titre values. Model fitting by Markov Chain Monte Carlo
(MCMC) yields estimates of the overall seroprevalence π
as well as the following parameters for every titre
category i: the proportion of positives in each titre
category, πi, and the proportion of seronegatives, θi, and
seropositives, φi, respectively, which have a titre value in
category i.
For the present analysis, titre ranges were defined
according to the following criteria: the first category
includes titres up to 10 arbitrary units (AU) in order to
justify the required assumption that the first category
contains no positives; the range of subsequent categories
was required to be no less than 30 AU and to contain a
minimum of 10 data points. The titre values of 40 unex-
posed Javanese individuals from Yogyakarta, Java, were
used as negative control group. The medians of the pos-
terior samples were used as point estimates for all
parameters. These are shown in Tables 1 (PfAMA-1)
and 2 (PfMSP-1), with the 95% Bayesian credible
intervals. The re-normalized probabilities πi and φi were
then divided by the size of the corresponding titre
category in order to obtain probability densities g-(x)
and g+(x).
Estimation of conversion and reversion rates using
Hidden Markov Models
Hidden Markov Models (HMM´s) are a popular, flexible
class of statistical time-series models, which can be seen
as a generalization of finite mixture models, as described
above, with the mixing ratio changing over time [14]. In
the present context, the sequence of observed titres x =
(x1. . .xn), obtained from one subject at surveys 1..n, is
seen as the result of a “hidden” (unobserved) sequence
of states h = (h1. . .hn), with ht corresponding to the sero-
logical state at survey t. The titre xt at time t is
distributed according to a particular PDF ght (x), condi-
tional on the hidden state ht. Transitions between hid-
den states occur with probabilities q(ht-1, ht). This
implies a major simplifying assumption of HMM's: the
stochastic process governing state transitions is without
memory, and only the immediately preceding hidden
state influences transitions. Further, the progression
through antibody levels after seroconversion is not expli-
citly modelled, but simply summarized in the titre distri-
bution among positives.
Two distinct continuous-time models for the transi-
tion of individuals between hidden states were compared
(Figure 1). Model 1 corresponds exactly to the reversible
catalytic model described above, with a negative and
a positive serological state, and seroconversion and
-reversion rates λ and ρ, respectively. The distribution of
antibody titres in either state corresponds to the
estimates of the negative and positive component, re-
spectively, as obtained from the mixture separation
Table 1 Mixture decomposition (AMA-1)
i Titre range πi ϕi θi
1 -∞ < t < 10 0 (by definition) 0 (by definition) 0.247 (CI: 0.219 - 0.276)
2 10 < t < 40 3.06E-5 (CI: 1.67E-8 – 5.52E-3) 8.52E-4 (CI: 7.25E-7 – 0.0755) 0.382 (CI: 0.349 – 0.414)
3 40 < t < 70 8.26E-5 (CI: 5.59E-8 – 0.0108) 1.02E-3 (CI: 1.17E-6 – 0.0621) 1.68E-1 (CI: 1.44E-1 – 0.194)
4 70 < t < 100 2.21E-4 (CI: 2.12E-7 – 0.0208) 9.88E-4 (CI: 1.58E-6 – 0.0415) 0.0600 (CI: 0.0454 – 0.0772)
5 100 < t < 130 6.03E-4 (CI: 8.08E-7 – 0.0390) 1.59E-3 (CI: 3.70E-6 – 0.0444) 0.0356 (CI: 0.0245 – 0.0495)
6 130 < t < 160 1.63E-3 (CI: 3.01E-6 – 0.0706) 3.18E-3 (CI: 1.05E-5 – 0.0593) 0.0263 (CI: 0.0170 –0.0383)
7 160 < t < 190 4.38E-3 (CI: 1.17E-5 – 0.125) 5.92E-3 (CI: 3.02E-5 – 0.0741) 0.0182 (CI: 0.0107 – 0.0285)
8 190 < t < 228 0.0115 (CI: 5.003E-5 – 0.209) 9.77E-3 (CI: 7.91E-5 – 0.0831) 0.0113 (CI: 5.61E-3 – 0.0198)
9 228 < t < 258 0.0300 (CI: 1.97E-4 – 0.332) 0.0281 (CI: 3.87E-4 – 0.156) 0.0124 (CI: 6.43E-3–0.0213)
10 258 < t < 541 0.0748 (CI: 8.63E-4 – 0.485) 0.0657 (CI: 1.70E-3 – 0.244) 0.0113 (CI: 5.57E-3 – 0.0198)
11 541 < t < 710 0.174 (CI: 3.68E-3 – 0.644) 0.163 (CI: 0.0100 – 0.418) 0.0112 (CI: 5.60E-3 – 0.0197)
12 710 < t < 1547 0.352 (CI: 0.0156 – 0.801) 0.384 (CI: 0.0838 – 0.794) 0.0113 (CI: 5.60E-3 – 0.0198)
13 1547 < t < 1730 0.577 (CI: 0.0415 – 0.942) 0.161 (CI: 0.0187 – 0.818) 1.95E-3 (CI: 2.88E-4 – 6.45E-3)
Medians and Bayesian Credible Intervals (CI, 2.5th to 97.5th percentile) of the estimated seroprevalence πi in each titre range i and the probabilities ϕi and θi that a
seropositive or -negative person, respectively, has an AMA-1 titre in range i. The overall seroprevalence π was 0.0169 (CI: 6.24E-4 – 0.0888). The titres of 40
unexposed individuals living in Yogyakarta served as negative control group.
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described above. Model 2 introduces an additional posi-
tive state, “positive at start”, with a separate reversion
rate γ. This parameter is not of direct interest, but serves
the purpose of “absorbing” the transmission history of
the study population: Model 1 ignores that subjects who
converted long before the study started may revert at a
different rate – faster or slower. An estimate of the re-
version rate, which is the inverse of the mean duration
of seropositivity and, therefore, itself of interest, would
thus be biased. For PfAMA-1 and PfMSP-1 antibody
data separately, the two models were compared with re-
spect to goodness of fit by means of the deviance infor-
mation criterion (DIC). Smaller values of DIC indicate a
better fit to the data [17].
Likelihood computations
The set of possible hidden states, denoted by S,
comprises a negative and a positive state in the case of
Model 1 (S = {1, 2}), and one negative and two positive
states in the case of Model 2 (S = {1, 2, 3}), as illustrated
in Figure 1. The intensity matrix I, which indicates the
flow from each state i (rows) to each other state j
(columns), takes the form
I1 ¼ λ λρ  ρ
 
for Model 1, and
I2 ¼
γ γ 0
0  λ λ
0 p  p
2
64
3
75
for Model 2. For each intensity matrix I, the corresponding
matrix Q, containing the discrete-time transition probabil-
ities q(i, j) from state i (rows) to state j (columns) during
one survey interval, can then be obtained as Q = eI, which
is equivalent to integration of the system of ordinary
differential equations defined by I over one time unit.
The likelihood p(xt|ht, g-, g+) of a single titre obser-
vation in an individual equals g-(xt) if the hidden
state ht is negative, and g+(xt) if it is positive. How-
ever, since the hidden state sequence is unknown, the
overall likelihood is computed as a weighted average
of likelihoods across all possible hidden sequences
[14]. Likelihoods are weighed by the probability of
each hidden sequence occurring, which can be
obtained from the probability β(h1) of being in a par-
ticular state h1 at the first survey, and the transition
probabilities between successive states, q(ht-1, ht). In
the present analysis, β(h1) was estimated as a free
parameter separately for each individual. The mar-
ginal likelihood of the data given the state transition
Figure 1 Models for the transitions between serological states. Two models for the transition of individuals from positive (top row) to
negative (bottom row) serological states over the course of the study: Model 1 assumes one positive and one negative state, with conversion
rate λ and reversion rate ρ. Model 2 treats individuals separately which are already seropositive at the start of the study. Those revert at a rate γ,
which may be different from ρ. Titre distributions in positive and negative individuals are schematically indicated on the left.
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rates can thus for one individual be written as follows
(details in notation omitted):
p xð Þ ¼
X
h∈Sn
p x; hð Þ
¼
X
h∈Sn
β h1ð Þpðx1 h1j Þ
Yn
t¼2
q ht1; htð Þp xt htj Þ;ð ð4Þ
and Σi log(p(xi) of the likelihoods for every person i
yields the overall log-likelihood for the data on one
particular antibody. Parameter estimates and Bayesian
Credible Intervals were obtained for each antibody
type separately by Bayesian Markov-Chain-Monte-Carlo
(MCMC) simulation, carried out using the JAGS program
[18] in conjunction with the R statistical software [19]. For
all parameters, non-informative uniform prior distributions
were chosen.
Finding individuals which seroconverted during the study
The individuals which most likely seroconverted during
the study period were identified by calculating for every
survey pair the probability that seroconversion occurred
based on the combined titre changes of both antibodies,
PfAMA-1 and PfMSP-1. Given the titres at the two
surveys xAMA11 ; x
AMA1
2 ; x
MSP1
1 ; x
MSP1
2 , summarized as X,
and the PDFs of the corresponding mixture components,
gAMA1 ; g
AMA1
þ ; g
MSP1
 ; g
MSP1
þ , summarized as G, this prob-
ability can be calculated as follows: let
gAMA1h1 x
AMA1
1
 
gAMA1h2 x
AMA1
2
 
gMSP1h1 x
MSP1
1
 
gMSP1h2 x
MSP1
2
 
¼ Ph1h2 X Gjð Þ
be the likelihood of the data given one of the four pos-
sible hidden state sequences, and assume that all of
these are equally likely before considering the data (i.e.
have prior probability 1/4), then the probability of sero-
conversion is
pþ X Gj Þð
p X Gj Þð þ pþ X Gj Þð þ pþ X Gj Þð þ pþþ X Gj Þð
¼ Pr h1 ¼ ; h2 ¼ þð Þ ð5Þ
via Bayes' Theorem. This probability was calculated for
every pair of observations in every individual in order to
find those with the highest probability of conversion.
All analyses were performed using the R statistical
software package [19], in conjunction with JAGS [18] for
Bayesian analyses.
Results
Of the 137 study participants, the number of microscopy-
positive individuals at rounds 1 through 4 (Dec-Mar) was
7, 3, 2, and 1, respectively. The corresponding point
prevalences are 0.05, 0.02, 0.01 and 0.007. No positives
were found at rounds 5 and 6.
The median antibody titres and corresponding inter-
quartile ranges (IQR) per round were 36 (15–64), 31
(16–72), 38 (19–64), 24 (12–66), 20 (8–55) and 12
(5–41) for AMA-1, and 54 (19–165), 37 (7–121), 45
(15–143), 65 (18–136), 49 (17–139) and 48 (10–118) for
MSP-1. The titre distributions are shown in Figure 2. A
Kruskal-Wallis test indicated that AMA-1 titres differed
between time points (p < 0.0001), while MSP-1 titres did
not differ (p = 0.14).
The nonparametric Bayesian mixture decompositions
estimated an overall seroprevalence in the dataset of
0.0169 (CI: 6.24E-4 – 0.0888) for AMA-1 and 0.0168 CI
(6.27E-4 – 0.0863) for MSP-1. Outputs of the mixture
separation according to the method of [9] are given in
Table 1 (AMA-1) Table 2 (MSP-1), and Figure 3. Median
titre and IQR among negative controls was 11.6 (4.32 –
16.6) for AMA-1 and 30.3 (11.6 – 80.9) for MSP-1.
Of the Hidden Markov Models, Model 1 fitted both
AMA-1 as well as MSP-1- data better than Model 2, as
indicated by lower values of DIC (Table 3). Estimates of
the seroconversion rate λ by Model 1 are 0.0157 (CI
5.78E-4 – 0.0827) for AMA-1, and 0.0872 (CI 0.0235 –
0.210) for MSP-1. The corresponding rates of serorever-
sion, ρ, were 0.553 (CI 0.0404 – 1.71) and 2.26 (CI 0.892
– 4.34), respectively. Parameter estimates of Model 1
were not sensitive to changes in the uniform prior
distributions. In Model 2, only the reversion rate ρ
was not identifiable and showed strong dependence on
the prior distribution when fitted to the AMA-1 data.
Individuals 76, 70, and 78 experienced seroconversion
with near certainty (conversion probability > 95%). The
titre time series of these are shown separately for each
individual in Figure 4 (top row), and against the back-
ground of the entire study population in Figure 5. In
addition, individuals 80, 27, 18 and 30 may have
converted (conversion probability > 50%), but no clear
conversion event is visible by eye. The first three of these
are shown in Figure 4 (bottom row). For comparison, a
positivity threshold was defined using the log-
transformed titre values of the control group: a log-titre
larger than two (three) standard deviations from the
mean was considered positive. This corresponded to a
titre threshold at 252.8 (731.1) for MSP-1, and at 79.9
(243.5) for AMA-1. By this method, 14 (5) conversions
were counted in the MSP-1 data, and 32 (13) conver-
sions using AMA-1. The count of reversions was 24 (6)
for MSP-1, and 40 (11) for AMA-1.
Discussion
The significant decrease of (only) anti AMA-1 antibody
titres and the decreasing number of parasite-positive
individuals are consistent with the seasonal drop in
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transmission intensity in the study area. A rolling cross-
sectional study in the same area, where the peak of
transmission occurred in December, found no parasites
during the dry season from April to August (Supargiyono,
unpublished). SCR estimates by the best-fitting HMM
indicate very small levels of P. falciparum transmis-
sion during the study period, with estimates based on
AMA-1 considerably lower than those based on MSP-1:
0.0157 person-1 year-1 for AMA-1 and 0.0872 person-1 -
year-1 for MSP-1. These SCR estimates are based on the
proportion of seronegative individuals who convert and
become seropositive per year. Although infections in
positive individuals are “not counted” by the model,
the rate estimates are unbiased since the denominator
contains only the number of persons at risk of con-
verting (the seronegatives). The rate estimates imply
that one should expect to find between 0.896 and
4.98 infection events in the present dataset, where
137 individuals were followed for 5 months. This is
compatible with the findings from the pairwise ana-
lysis which found three individuals who almost cer-
tainly experienced infection (conversion probability >
95%), and an additional four which may have done so
(conversion probability > 50%).
Figure 2 Distribution of AMA-1 and MSP-2 titres. The titre distribution of anti AMA-1 (a) and anti MSP-1 (b) antibodies in the study
population, all survey rounds pooled.
Table 2 Mixture decomposition (MSP-1)
i titre range πi ϕi θi
1 -∞ < t < 10 0 (by definition) 0 (by definition) 0.932 (CI: 0.157 – 0.209)
2 10 < t < 40 3.94E-7 (CI: 6.62E-11 – 2.31E-4) 7.43E-6 (CI: 1.93E-9 – 2.67E-3) 0.264 (CI: 0.236 – 0.294)
3 40 < t < 70 1.05E-6 (CI: 2.29E-10 – 4.76E-4) 1.08E-5 (CI: 3.55E-9 – 2.91E-3) 0.1413 (CI: 0.119 – 0.166)
4 70 < t < 100 2.82E-6 (CI: 8.20E-10 – 9.84E-4) 1.59E-5 (CI: 7.16E-9 – 3.21E-3) 0.0774 (CI: 0.0608 – 0.0965)
5 100 < t < 130 7.57E-6 (CI: 2.73E-9 – 2.04E-3) 4.61E-5 (CI: 2.61E-8 – 6.99E-3) 0.0831 (CI: 0.0661 – 0.103)
6 130 < t < 160 2.06E-5 (CI: 1.00E-8 – 4.09E-3) 7.23E-5 (CI: 5.58E-8 – 7.86E-3) 0.0484 (CI: 0.0354 – 0.0640)
7 160 < t < 190 5.57E-5 (CI: 3.76E-8 – 8.28E-3) 1.82E-4 (CI: 1.94E-7 – 0.0146) 0.0449 (CI: 0.0325 – 0.0599)
8 190 < t < 220 1.51E-4 (CI: 1.39E-7 – 0.0159) 3.13E-4 (CI: 4.49E-7 – 0.0175) 2.87E-2 (CI: 1.89E-2 – 0.0412)
9 220 < t < 250 4.06E-4 (CI: 4.99E-7 – 0.0310) 9.43E-4 (CI: 1.85E-6 – 0.0362) 3.20E-2 (CI: 2.17E-2 – 0.0452)
10 250 < t < 280 1.10E-3 (CI: 1.85E-6 – 0.0580) 1.35E-3 (CI: 3.79E-6 – 0.0360) 1.70E-2 (CI: 9.79E-3 – 0.0272)
11 280 < t < 310 2.96E-3 (CI: 6.88E-6 – 0.104) 2.66E-3 (CI: 1.13E-5 – 0.0465) 1.24E-2 (CI: 6.42E-3 – 0.0213)
12 310 < t < 358 7.92E-3 (CI: 2.73E-5 – 0.180) 6.51E-3 (CI: 4.12E-5 – 0.0733) 1.12E-2 (CI: 5.59E-3 – 0.0198)
13 358 < t < 442 0.0210 (CI: 1.13E-4 – 0.291) 0.0176 (CI: 1.87E-4 – 0.124) 0.0112 (CI: 5.59E-3 – 0.0197)
14 442 < t < 561 0.0539 (CI: 4.93E-4 – 0.431) 0.0467 (CI: 8.72E-4 – 0.206) 1.12E-2 (CI: 5.56E-3 – 0.0198)
15 561 < t < 781 0.129 (CI: 2.20E-3 – 0.587) 0.120 (CI: 4.82E-3 – 0.343) 0.0112 (CI: 5.55E-3 – 0.0197)
16 781 < t < 1029 0.278 (CI: 9.45E-3 – 0.741) 0.283 (CI: 0.0351E-2 – 0.610) 0.0113 (CI: 5.57E-3 – 0.0198)
17 1029 < t < 1417 0.500 (CI: 0.0323 – 0.888) 0.399 (CI: 0.122 – 0.932) 6.60E-3 (CI: 2.58E-3 – 0.0136)
Medians and Bayesian Credible Intervals (CI, 2.5th to 97.5th percentile) of the estimated seroprevalence πi in each titre range i and the probabilities ϕi and θi that a
seronegative or -positive person, respectively, has an MSP-1 titre in range i. The overall seroprevalence π was 0.0168 CI (6.27E-4 – 0.0863). The titres of 40
unexposed individuals living in Yogyakarta served as negative control group.
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All individuals which converted with probability > 95%
also tested parasite positive either at the same survey
(ind. 76), before (ind. 78) or after (ind. 70) the antibody
response (Figure 4). Because the sensitivity of micros-
copy is far from perfect [20] it is difficult to determine
the exact time point of infection from microscopy data.
This might explain antibody responses which precede
microscopic detection, but a delayed antibody response
may indicate that not all hosts respond immediately
and/or against all antigens of a parasite, an idea that
appears plausible when looking at the titres of indivi-
duals that ever tested positive by microscopy (Additional
file 1). Future analyses might thus consider using a lar-
ger number of antigens simultaneously, and extend the
statistical methods accordingly.
The consistency of model-based SCR estimates with
the number of conversion events identified by pairwise
comparison of titres demonstrates that the HMM ap-
proach is both robust against noise in titre measure-
ments as well as highly sensitive at detecting low
levels of serological incidence. It may thus be used
to measure the FOI at very low levels of transmis-
sion, which may be encountered in a near-elimination
scenario or when preventing re-introduction of the
disease after successful elimination. Once malaria has
completely disappeared or is very rare, it is ethically
problematic to collect large numbers of blood sam-
ples for the purpose of measuring transmission inten-
sity [2]. However, antibody titres can also be measured
non-invasively from saliva samples, which would allow
large-scale screening of affected populations [21]. Se-
rological cohort-data from saliva samples in conjunc-
tion with the statistical analysis approach presented here
may thus represent a formidable tool for post-elimination
surveillance.
In addition to the rate of conversion, the HMM's
yield an estimate of the rate of sero-reversion which is
the inverse average duration of seropositivity. The dura-
tion of seropositivity is likely to be different in children
compared to adults due to physiological changes with
age; in addition, it may differ between antigens, and is
expected to increase with cumulative exposure. The dur-
ation of seropositivity, and how it is affected by the
above factors, is of major interest for the planning of
studies which use antibodies for epidemiological mo-
nitoring and for choosing the best-suited antigens. In
Figure 3 Results of the mixture decomposition. Graphical representation of the estimated probability densities of the titre distributions in
seronegative and -positive individuals, respectively, for both AMA-1 (a) and MSP-1 antibodies (b). An average of the PDFs, weighted by relative
abundance of positive and negative individuals, approximately yields the PDF of the titre data.
Table 3 Parameter estimates
AMA-1
Model λ ρ γ DIC
1 0.0157 (5.78E-4 – 0.0827) 0.553 (0.0404 – 1.71) n.a. 2964
2 0.0187 (7.09E-4 – 0.103) 5.58 (0.308 – 9.80) 0.541 (0.0389 – 1.68) 2968
MSP-1
Model λ ρ γ DIC
1 0.0872 (0.0235 – 0.210) 2.26 (0.892 – 4.34) n.a. 3829
2 0.0875 (0.0235 – 0.209) 0.926 (0.0328 – 5.49) 3.12 (1.23 – 6.52) 3833
The seroconversion rate λ and reversion rates ρ and γ as estimated by Models 1 and 2 (person-1 year-1) are shown with 95% Bayesian credible intervals. Models
were fitted to AMA-1 and MSP-1 data separately. Lower values of Deviance Information Criterion (DIC) indicate a better fit to the data.
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addition, the change in duration of antibody responses
in response to cumulative exposure has the potential to
yield further insight into the acquisition of immuno-
logical memory against malaria. The present analysis
attempted to obtain estimates of the seroreversion rate
which are unbiased by the exposure history of the study
population; a central assumption of a HMM is that the
probability of reversion at any moment is independent
of how long the individual has already been positive.
Since this is not strictly true in the biological counter-
part, Model 2 was devised to “absorb” the bias on rever-
sion rate estimates introduced by individuals already
positive at the start of the study. However, Model 1 fit-
ted the data better, which suggests that the present
dataset does not contain enough information to measure
reversion rates strictly from individuals which converted
Figure 4 Seroconverting individuals. Those individuals most likely experiencing seroconversion during the study period are displayed in
descending order of conversion probability, as determined from pairs of surveys. Only individuals 76, 70 and 78 appear to have converted with
near certainty, and do not revert within the study period. Black dots indicate the presence of parasites in blood slides. Since parasitaemic
individuals were always treated, those may represent re-infections.
Figure 5 Titre time series. Antibody titre time series of the three individuals which likely seroconverted during the study (red) are shown
against the background of the whole study populations; separately for antibodies against AMA-1 (a) and MSP-1 (b).
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(and reverted) during the study. This is in line with the
observation that none of the three clearly converting
individuals (Figure 5, top row) appears to revert during
the study. The estimates of ρ obtained from Model 1
thus provide only limited information on the actual dur-
ation of seropositivity. In principle, however, the present
approach allows measurement of the duration of anti-
body responses, but cohort data are required where
enough individuals both convert and revert during the
study period. Ideally, this requires larger datasets where
transmission intensity is somewhat higher but still low
enough such that multiple concurrent infections per per-
son are rare. Effects of individual inoculations on anti-
body responses would then remain distinguishable.
The advantages of the statistical methods used in the
present analysis, compared to threshold-based methods,
are mostly in their robustness towards noise in the titre
measurements as well as in their comparatively solid
theoretical foundation. The pairwise analysis yields a
probability measure indicating whether seroconversion
has happened (with values close to 1.0 equivalent to near
certainty), based on relatively few assumptions. The
HMMs propagate uncertainties concerning serological
status into the conversion- and reversion rate estimates,
in form of wider credible intervals. The number of
seroconversions and -reversions recorded using the
cutoff method depended strongly on the (arbitrary) nu-
merical value of the positivity threshold; generally, more
conversions/reversions were counted. It appears plaus-
ible that random fluctuations in the titre measurements
created “false” conversion and reversion events, which
renders SCR estimates obtained in this manner rather
unreliable. The approaches introduced in this article, in
contrast, are more robust because they weigh large titre
changes more than small ones, thereby making better
use of the information in the data.
The uncertainty in the present SCR estimates is con-
siderable, in fact similar in magnitude as the estimates
themselves. This is not only due to the uncertainty in
classifying individuals as positive or negative, but be-
cause sample size and duration of follow up are rather
small and do not allow for more precise measurement
of such low-intensity transmission, even if a perfect me-
thod of identifying infections were available. Figure 6
illustrates the relationship between the theoretical limits
of measuring transmission intensity and the dimensions
of a study. The underlying model assumes that a non-
heterogeneous force of infection is acting on a study
population, and that a perfect method for counting
infections is available. The number of infection observed
Figure 6 Theoretical limits for measuring transmission intensity in cohort studies. Measuring the force of infection (FOI) in a cohort study
by detecting infection events is subject to the theoretical limitations governing count data: under idealizing assumptions the number of
infections in a study is Poisson-distributed with expectation equal to FOI x the number of study subjects x study duration. This introduces
uncertainty into FOI estimates. An example: in order to measure a FOI with ca. ± 25% accuracy, on average 50 infections need to happen during
a study. At a FOI of 0.1, this can be achieved by following 500 individuals for 1 year, or 250 individuals for 2 years, etc.
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is then Poisson-distributed. This introduces uncertainty
into the corresponding rate estimates. For the present
study with three detected infections, estimates from
0% to 200% of the true value are to be expected, even
with optimal methods. The scarcity of conversion events
in this data also precludes addressing seasonality of
transmission.
Conclusions
Serological cohort studies are an efficient means of
obtaining information on the FOI in areas of very low
transmission and single conversion events may be
detected. The statistical methods presented here suggest
that this approach could be a useful adjunct measure to
existing measures of transmission such as clinic based
incidence rates especially if targeted to easy access
groups. More serological data are required from cohorts
resident at different endemicities to further validate the
approach.
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Additional file 1: A plot of the data from all individuals with at
least one positive microscopy result.
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